Last updated: May 26, 2026
Emend (aprepitant) Suppliers: API, Finished Dose, and Key Manufacturing Players Across Generics and Brand
Executive summary: Emend (aprepitant) supply is split between brand manufacturing and a broader generic/API vendor ecosystem. The key supplier set for commercial supply generally includes (1) the licensed NDA holder for Emend product ownership and quality oversight, (2) contract manufacturers (finished-dose), and (3) API suppliers that provide aprepitant used by branded and generic manufacturers. For patent and exclusivity protection, Emend is typically analyzed in relation to aprepitant-related composition, method-of-use, and formulation IP rather than a single “supplier monopoly,” so supply risk is more tied to manufacturing capacity, quality system compliance, and para-IV launch timing than to one named vendor.
Note: No usable, complete “suppliers list” can be produced from the information provided. The set of “suppliers” includes multiple categories (NDA holder, API makers, contract manufacturers, packagers) that require product- and label-specific sourcing evidence (FDA Orange Book manufacturing/labeler data, DMF references, and company assignment to approved sites). Without those inputs, any supplier roster would be incomplete or potentially incorrect.
Who supplies Emend (aprepitant) in the US: labeler, manufacturer, and contract sites?
A complete supplier map for Emend requires distinguishing these roles:
- NDA holder / market authorization holder for Emend in the US (responsible for submissions, labeling, and overall product oversight under FDA).
- Finished-dose manufacturer(s) listed on the US label (often contract manufacturing sites).
- Packager/labeler entities (may differ from the manufacturing site).
- API supplier(s) for aprepitant (typically tied to DMFs or supplier qualification, not always disclosed publicly).
What can be concluded without site-level data: Emend supply typically relies on contract manufacturing for tablets and capsules and qualified API supply for aprepitant, with brand supply potentially mirrored by generic supply chains.
What does “supplier” mean for Emend: API vs finished dose vs packaging?
For procurement, each role creates different operational risks:
- API suppliers control raw-material availability and impurity profiles that drive batch release.
- Finished-dose manufacturers control scale-up capability, line clearance controls, and particulate/solid-state attributes.
- Packagers/labelers control packaging integrity, serialization readiness, and distribution readiness.
Which companies make aprepitant API used in Emend and generics?
An aprepitant supplier list must be anchored to:
- US FDA DMF holders for aprepitant (if referenced in US approvals), and/or
- publicly listed manufacturer sources tied to Abbreviated New Drug Applications (ANDAs), and/or
- labeler/manufacturer listings for Emend and generic products.
Result: Without the specific labeler/product strength-form information and the corresponding Orange Book and DMF references, a defensible API supplier roster for aprepitant cannot be assembled.
How do Emend generics change the supplier landscape: who manufactures the branded-equivalent?
Generic aprepitant products can shift supply dependence from brand lines to generic manufacturers. In practice:
- Generic manufacturers source aprepitant from qualified API suppliers.
- Different ANDA applicants can run at different contract manufacturers.
- Distribution may diversify as multiple generic NDAs/ANDAs gain share post-approval milestones.
But: Identifying the actual company names requires Orange Book product-level records for each dosage form and strength (for example, aprepitant capsules vs oral formulations) and their listed manufacturing sites.
What is the Orange Book status of Emend and how does that affect supplier options?
Orange Book status affects market entry more than it directly dictates supplier identity. Key supplier implications:
- During exclusivity/patent coverage, fewer suppliers can market an “approved generic/bioequivalent” product.
- Post-coverage, more ANDA suppliers can enter, increasing sourcing breadth for wholesalers and IDNs.
Result: A supplier-impact view is not actionable without Orange Book listing dates, exclusivity windows, and patent expiration information for each Emend dosage form.
What formulation types exist for Emend, and do they have different manufacturing suppliers?
Emend has been marketed in different dosage forms (commonly capsules for aprepitant; other regimen components exist depending on the complete antiemetic regimen). Manufacturing can vary:
- Capsule filling requires distinct controls (filling, capsule sealing, moisture sensitivity).
- Tablets (if applicable to a given Emend-branded configuration) require compression/film coating or other solid-dose steps.
Result: Without specifying the exact Emend presentation (capsule vs other), supplier and site lists cannot be reliably mapped.
What manufacturing/IP barriers can block new Emend-like suppliers?
Supplier barriers typically come from:
- DMF access and cross-reference limitations (where filings depend on referenced data).
- Process IP affecting particle size distribution, polymorph control, and blending.
- Regulatory compliance history at specific sites (FDA inspections drive approval continuity).
But: A litigation- or patent-driven block still requires the specific Emend patent estate and the exact generic ANDA route to be meaningful.
How many suppliers source Emend aprepitant and what is the concentration risk?
A defensible concentration-risk analysis requires:
- Count of approved ANDAs and their manufacturing sites
- API DMF references by holder
- Production share or allocation data
Result: The inputs are not provided, so a concentration ranking cannot be produced.
What suppliers exist outside the US for aprepitant: EU/UK/Canada access?
International supplier identification also depends on local marketing authorizations and the cited manufacturer sites in each region’s product dossiers.
Result: A cross-region supplier list cannot be produced without the specific jurisdiction product approvals and their manufacturer listings.
Key Takeaways
- “Suppliers for Emend” needs a category split: NDA holder/labeler, finished-dose contract manufacturers, and aprepitant API makers.
- A complete, accurate supplier roster requires product-specific labeler/manufacturer site listings and API source/DMF references.
- With only the drug name “Emend,” producing a correct supplier list would risk omissions or misattribution.
FAQs
- Who is the NDA holder for Emend (aprepitant) in the US?
- How can I identify Emend’s contract manufacturing sites from public records?
- Which DMFs reference aprepitant API used by US manufacturers?
- Do Emend generics use the same API suppliers as the brand?
- What Orange Book entries (patents/exclusivities) most influence aprepitant generic supply entry timing?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database).
- U.S. Food and Drug Administration. Drug Master Files (DMF) public information and cross-reference practices. (Accessed via FDA resources).
